Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

Neuro-Oncology

Volumn 18, Issue 2, 2016, Pages 283-290

  De La Fuente, MacArena I ^a,c,g   Young, Robert J ^a   Rubel, Jennifer ^a   Rosenblum, Marc ^a   Tisnado, Jamie ^a   Briggs, Samuel ^a   Arevalo Perez, Julio ^a   Cross, Justin R ^a   Campos, Carl ^a   Straley, Kimberly ^b   Zhu, Dongwei ^b   Dong, Chuanhui ^c   Thomas, Alissa ^a   Omuro, Antonio A ^a   Nolan, Craig P ^a   Pentsova, Elena ^a   Kaley, Thomas J ^a   Oh, Jung H ^a   Noeske, Ralph ^d   Maher, Elizabeth ^e   Choi, Changho ^e   Gutin, Philip H ^a   Holodny, Andrei I ^a   Yen, Katharine ^f   Deangelis, Lisa M ^a   Mellinghoff, Ingo K ^a   Thakur, Sunitha B ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AGIOS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e GE HEALTHCARE   (Germany)

^f Weill Cornell Medical Center   (United States)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

cancer metabolism; glioma; IDH; imaging biomarker; magnetic resonance spectroscopy; R 2 hydroxyglutarate

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURGERY; CELL PROLIFERATION; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIFFUSION COEFFICIENT; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MUTATIONAL ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME; BRAIN NEOPLASMS; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM GRADING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; YOUNG ADULT;

EID: 84960430663     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov307     Document Type: Article

References (31)

1. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
2. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
3. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):485-U144.
4. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-483.
5. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
6. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
7. Stein E, Tallman M, Pollyea DA, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014 Apr 5-9; San Diego, CA, Philadelphia (PA): AACR;
8. Cancer Res. 2014;74(Suppl 19):103.
9. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274): 739-744.
10. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.
11. Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. 2012;131(3):766-768.
12. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):1-22.
13. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629.
14. Sandgren N, Stoica P, Frigo FJ, Selen Y. Spectral analysis of multichannel MRS data. J Magn Reson. 2005;175(1):79-91.
15. Bal D, Gryff-Keller A. 1H and13C NMR study of 2-hydroxyglutaric acid and its lactone. Magn Reson Chem. 2002;40(8):533-536.
16. Govindaraju V, Young K, Maudsley A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129-153.
17. Bydder M, Hamilton G, Yokoo T, Sirlin CB. Optimal phased-array combination for spectroscopy. Magn Reson Imaging. 2008;26(6): 847-850.
18. Wright S, Wald L. Theory and application of array coils in MR spectroscopy. NMR Biomed. 1997;10:394-410.
19. Schubert FSF, Elster C, Link A, et al. Improvement of the analytical quality of MR spectroscopy data by frequency corrected averaging [abstract]. Magn Reson Mat Physiol Biol Med. 2000;11(Suppl. 1): 189.
20. Thompson R, Allen P. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn Reson Med. 1999;41(6): 1162-1169.
21. Kalpathy-Cramer J, Gerstner ER, Emblem KE, Andronesi OC, Rosen B. Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res. 2014;74(17): 4622-4637.
22. Bottonley P. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-348.
23. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
24. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-Grade gliomas. N Engl J Med. 2015;372(26): 2481-2498.
25. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508.
26. Mabray MC, Barajas RF Jr., Cha S. Modern brain tumor imaging. Brain Tumor Res Treat. 2015;3(1):8-23.
27. Al-Okaili RN, Krejza J,Wang SM,Woo JH, Melhem ER. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics. 2006;26:S173-SU84.
28. Salvolini U, Scarabino T. High Field Brain MRI: Use in Clinical Practice. Berlin: Springer Verlag; 2010.
29. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121(24): 4917-4924.
30. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012;120(23):4649-4652.
31. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339-344.